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ABSTRACT 
Objective. To examine the frequency of impaired spinal mobility in patients with chronic 
back pain of short duration and to compare the frequency of impaired spinal mobility in 
patients with axial spondyloarthritis (axSpA), possible SpA and no SpA. 
Methods.  The SpondyloArthritis Caught Early (SPACE) cohort includes patients with chronic 
back pain (≥3 months, ≤2 years, onset <45 years). Spinal mobility was assessed with lateral 
spinal flexion, chest expansion, cervical rotation, occiput-to-wall distance, and lumbar 
flexion. Hip mobility was assessed with intermalleolar distance. Mobility measures were 
defined as impaired if below the 5th percentile reference curve from general population, 
adjusted for age and height when appropriate. Proportions of patients categorized with 
impaired mobility were examined with chi square. 
Results. In total, 393 patients with chronic back pain were included: 142 axSpA, 140 possible 
SpA and 111 no SpA. Impairment in ≥1 mobility measure was present in 66% of all patients. 
The most frequently impaired mobility measure was lateral spinal flexion (40%), followed by 
chest expansion (22%), cervical rotation (18%), intermalleolar distance (17%), lumbar flexion 
(15%) and occiput-to-wall distance (11%). No statistically significant differences in 
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proportion of patients with impaired spinal mobility were found between patients with 
axSpA and the other subgroups in any of the tests. 
Conclusion. Two out of 3 patients with chronic back pain of short duration had impaired 
spinal mobility compared to general population. Impaired spinal mobility occurs as often in 
patients with early axSpA as in other forms of chronic back pain.  
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INTRODUCTION 
Back pain is one of the most common musculoskeletal disorders, affecting up to 80% of the 
population at some point in life (1) and represents large individual and societal costs (1, 2). 
Most patients with back pain experience a natural recovery within some weeks. However, 
symptoms and functional limitations remain over time in about 10% (1) and some of these 
patients have an inflammatory rheumatic disease, such as axial spondyloarthritis (axSpA) (3-
6). AxSpA is characterized by inflammatory back pain and progressive restriction in spinal 
mobility (7) with available treatments allowing us to improve health related quality of life 
through control of symptoms and inflammation as the primary treatment goal (8).  
 
Early initiation of treatment is considered to be favourable in the disease course of patients 
with axSpA, and the response to tumour necrosis factor inhibitor (TNFi) therapy may be 
better when initiated early in the disease course (9, 10). Further, regular exercise is included 
in the management recommendation throughout the disease course (8) and is shown to 
reduce disease activity and improve spinal mobility (11) even in patients receiving stable 
TNFi therapy (12). Because effective treatment is available, it is important to recognize 
patients with inflammatory rheumatic disease among the large group of patients with 
chronic back pain.  
 
Reduced spinal mobility is regarded as an important clinical feature of axSpA, emphasised by 
the inclusion in the core set of clinical assessment that has been defined by the Assessment 
of SpondyloArthritis international Society (ASAS) (13). Both structural damage and 
inflammation may contribute in spinal mobility impairment (14, 15). In early disease, 
impairments in spinal mobility is shown to be more influenced by inflammation, whereas in 
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later disease structural damage is also important (14). Lateral spinal flexion and the 
frequently used index of spinal mobility, the Bath Ankylosing Spondylitis Metrology Index 
(BASMI), have the best ability to discriminate between patients with and without structural 
damage in ankylosing spondylitis (AS) (15). However, according to the current ASAS 
classification criteria, axSpA patients can be classified before structural, radiographic 
changes have occurred, and the role of impaired spinal mobility as a disease-specific clinical 
feature in the early phase of the disease is not clear (16). Age-adjusted normal values have 
recently been defined for the spinal mobility measures, which enables comparing spinal 
mobility of patients with the general population (17). The objectives of our study were 
therefore to examine the frequency of impaired spinal mobility in patients with chronic back 
pain of short duration; and further, to compare the frequency of impaired spinal mobility 
between patients with axSpA and those with other forms of chronic back pain with similar 
symptom duration.  
 
MATERIAL AND METHODS 
Patients. Data from the SpondyloArthritis Caught Early (SPACE) cohort are used for this 
analysis. The SPACE cohort is a European ongoing observational inception cohort established 
in 2009 (18) and includes patients with chronic back pain for at least 3 months, not 
exceeding 2 years of duration, with an onset before the age of 45 years. All patients included 
in SPACE between January 2009 and December 2014 from the five rheumatology 
outpatients’ clinics are included in the current analysis; Leiden University Medical Center, 
Amsterdam Medical Center and Groene Hart Ziekenhuis, the Netherlands; University of 
Padova, Italy; and Diakonhjemmet Hospital, Norway. In the Netherlands the SPACE-protocol 
was approved by medical ethical committee in Leiden University Medical Center (P08.105), 
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in Norway by the regional committee for medical and health research ethics in South East 
Norway (2010/426) and in Italy by the Azienda Osperdaliera di Padova (2438P). The study 
was performed in compliance with the Helsinki agreement. All patients provided their 
written informed consent before participation. 
 
Assessments. Data used in the current study refer to the baseline visit, in which all patients 
underwent a diagnostic assessment for potential axSpA and were classified according to the 
ASAS axSpA criteria (16). Laboratory assessment consisted of HLA-B27 typing, erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). The presence or history of SpA 
features including inflammatory back pain, arthritis, enthesitis, uveitis, dactylitis, psoriasis, 
inflammatory bowel disease, response to nonsteroidal antiinflammatory drugs (NSAIDs) and 
family history of SpA were recorded (18). Imaging was obtained with plain radiographs of 
pelvis with anteroposterior view and magnetic resonance imaging (MRI) of the sacroiliac 
joints with a semi-coronal plane. All imaging was scored independently by 2 experienced 
readers in a central reading. The pelvic radiographs were scored according to the modified 
New York criteria (19) and MRIs were scored according to the ASAS definition of active 
sacroiliitis (20).  
 
For the purpose of this study patients were classified as having axSpA if they fulfilled the 
ASAS criteria for imaging and/or clinical axSpA (16). Patients who did not fulfill the ASAS 
criteria, were classified as possible SpA if they (1) presented with either sacroiliitis on 
imaging with no other SpA feature, (2) HLA-B27-positive with 1 other SPA feature, (3) ≥1 of 
the following SpA features; periperal arthritis, uveitis, dactylitis, heel enthesitis, psoriasis, 
inflammatory bowel disease, eleveted ESR/CRP, or (4) had these 3 SpA features; 
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inflammatory back pain, positive family history, and good response to NSAID. Patients were 
classified as no SpA if they had low possibility of having axSpA (e.g. either being HLA-B27-
positive with no other SpA feature or having  ≤2 of the following SpA features; inflammatory 
back pain, positive family history, or good response to NSAID). A detailed description of the 
categorisation of patients in the possible SpA and no SpA groups has been published 
previously (21). 
 
Information was collected about the patients’ age, gender, age at onset of back pain and 
duration of back pain, location of back pain, and current use of medication were collected. 
Body height and weight was measured and body mass index (BMI) was calculated (kg/m2); 
≥25.0 was categorised as overweight. In addition, intensity of back pain during the last week 
was assessed by the patients on an 11-point numeric rating scale, anchored by 0 “no pain” 
and 10 “unbearable pain”.      
 
Five measurements of spinal mobility and 1 measure of hip mobility were collected and 
performed following the recommendations from ASAS (13). Spinal mobility was assessed 
with lateral spinal flexion, chest expansion, cervical rotation, lumbar flexion measured 
according to the 10 cm Schober’s test and occiput-to-wall. Hip mobility was assessed with 
intermalleolar distance. All spinal mobility measurements were recorded in cm with 1 
decimal, except for cervical rotation, which was recorded in degrees. Intermalleolar distance 
was recorded in cm and rounded to integer unit. The better of 2 tries for each measurement 
was recorded. More details on the measurement are in Supplementary Table 1 (available 
with the online version of this article).  
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The composite index BASMI includes lateral spinal flexion, cervical rotation, lumbar flexion, 
intermalleolar distance and tragus-to-wall distance (22). To calculate BASMI, the values of 
tragus-to-wall were derived from the occiput-to-wall results by adding 8 cm (18). By doing 
so, the value of zero in the occiput-to-wall corresponds to 8 in tragus-to-wall used in the 
calculation of BASMI linear, both equivalents to no increased kyphosis (23, 24). Further, 
measures of tragus-to-wall and occiput-to-wall are known to be comparative across the 
entire scale (24). The formula for BASMI linear was used to compute the total score, ranging 
from 0-10 where the highest score represents most impairment (23). 
 
Reference data from the general population for lateral spinal flexion, chest expansion, 
cervical rotation, intermalleolar distance, lumbar flexion and BASMI were obtained from the 
MOBILITY study (17). The mobility measures, except BASMI, were defined as impaired if they 
fell below the reference values for the fifth percentile curve from the general population, 
adjusted for age for all measures, and for chest expansion and intermalleolar distance also 
for height (17).  The BASMI has inverse scoring; therefore reference values above the 95th 
percentile curve were defined as impaired. For occiput-to-wall, percentile curves could not 
be derived, and a cutoff of >0 was considered impaired. To analyze the sensitivity, we also 
performed the analyses with the 2.5th percentile curve as cutoff for impairment.   
 
Statistical analyses. Patient characteristics are presented as mean with standard deviation 
(SD) for continuous variables and as frequency (percentage) for categorical variables. 
Mobility measures and the BASMI are presented with mean (SD) for continuous variables 
with normal distribution or median with interquartile range for continuous variables with 
skewed distribution. Proportions of patients categorized with impaired spinal mobility are 
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presented as frequency (percentage). Overall group differences (definite, possible and no 
SpA) were examined with chi-square test for categorical variables, 1-way ANOVA for 
continuous normally distributed variables, and by Kruskal-Wallis test for continuous 
variables with skewed distributions. If statistically significant differences were detected in 
the overall group analyses, appropriate post-hoc analyses (chi-square test with Yates 
continuity correction, Fisher’s LSD test or Mann-Whitney U test) were applied. Statistical 
analyses were performed using SPSS version 21.0 (SPSS Inc.) and the figures were made in 
GraphPad Prism version 7.0 (GraphPad Software).    
 
RESULTS 
In total, 395 patients with chronic back pain were eligible, but 2 patients had insufficient 
information, so 393 were included in our present study. Of the included 393 patients, 142 
(36%) fulfilled the ASAS axSpA criteria, 140 (36%) were classified as possible SpA and 111 
(28%) as no SpA. In the axSpA group, 58 (41%) fulfilled the imaging arm (28 with radiographic 
sacroiliitis and 30 with active inflammation on MRI) and 84 (59%) the clinical arm only of the 
ASAS axSpA criteria. In the possible SpA group, 108 (77%) who had normal imaging were 
HLA-B27 negative and had ≥1 of the following SpA features; periperal arthritis, uveitis, 
dactylitis, heel enthesitis, psoriasis, inflammatory bowel disease or eleveted ESR/CRP. There 
were 20 (14%) HLA-B27 postitve patients with normal imaging and one SpA feature. Eight 
(6%) who had normal imaging were HLA-B27-negative, with the following 3 SpA features: 
inflammatory back pain, positive familiy history, and good response to NSAID. Four (3%) 
patients had positive imaging and no SpA features.  
The patients’ characteristics are shown in Table 1. Patients classified with axSpA were more 
frequently male (p<0.001) and HLA-B27-positive (p<0.001). They reported less back pain 
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(intensity) (p<0.001) but more commonly buttock pain (p=0.03), and less frequently lumbar 
pain (p=0.01).  There were no differences in age at onset or duration of back pain between 
the subgroups.  
 
Mobility measures are presented in Table 2. Comparisons between the subgroups showed 
that the axSpA group compared to possible SpA  and no SpA groups had statistically 
significant better intermalleolar distance (p=0.01) and better cervical rotation than the 
possible SpA group (p=0.01). There were no differences between the subgroups in the other 
mobility measures. In the BASMI, the axSpA–group had a lower score (better mobility) 
compared to possible SpA- and no SpA group (p=0.01).  
 
The proportions of patients categorized with impaired spinal mobility are shown in table 3. 
In all patients with chronic back pain, impairment in at least one mobility measure was 
present in 66% among those with complete assessment. The most frequently impaired 
mobility measure was lateral spinal flexion (40% of the patients) followed by chest expansion 
(22%), cervical rotation (18%), intermalleolar distance (17%) and lumbar flexion (15%) and 
occiput-to-wall (11%). Twenty-nine percent of the patients was categorised with impaired 
spinal mobility according to the composite score BASMI.  
 
There were no statistically significant differences in the proportion of patients categorised 
with impaired mobility according the single instruments among the chronic back pain 
subgroups in any of the mobility measures (Table 3). However, for the BASMI, in accordance 
with the scores, a statistically significant lower proportion of patients with axSpA (21%) had 
impaired mobility compared to possible SpA (33%) and no SpA (33%; p=0.03). There were no 
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statistically significant differences in the proportion of patients with impairment according to 
sex in any of the measures (data not shown). The distributions of lateral spinal flexion and 
BASMI in the subgroups are shown in Figure 1, with percentile curves illustrating the age 
specific spinal mobility cutoff as defined from the general population.  Details of other 
mobility measures are outlined in supplementary Figure 1-5 (available with the online 
version of this article).   
 
In the subgroup of patients with axSpA, impaired mobility in at least one measure was 
present in 58% among those with complete assessment of mobility measures (Table 3). 
Among those with at least 1 impaired measure, lateral spinal flexion was most frequently 
impaired in 47 out of 76 (62%). Among the remaining 29 (38%) patients, chest expansion was 
most frequently impaired in 14 (48%), followed by cervical rotation in 9 (31%), occiput-to-
wall distance 8 (28%), intermalleolar distance 7 (24%), and lumbar flexion 7 (24%).  
The proportions categorized with impaired mobility were compared between patients 
fulfilling the ASAS criteria for axSpA according to radiographic sacroiliitis, active sacroiliitis on 
MRI and clinical arm, and no statistically significant difference were seen in neither of the 
mobility measures. Sensitivity analyses with the 2.5th percentile curve as cutoff showed 
similar results (data not shown).  
 
DISCUSSION  
In this study of patients with chronic back pain of short duration, we have shown that spinal 
mobility was impaired in 1 or more mobility measures in 66% of patients and that the most 
frequently impaired mobility measure was lateral spinal flexion. However, mobility measures 
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recommended for axSpA are as frequently impaired in patients with early axSpA as in those 
with other causes of chronic back pain. 
 
To our knowledge, this is the first study comparing spinal mobility in patients with chronic 
back pain with age-adjusted percentile curves from the general population. Large variations 
in spinal mobility are demonstrated in the general population (17, 25, 26). Even so, in our 
current study 2 out of 3 of patients with chronic back pain had impaired mobility in 1 or 
more measures, defined as below the fifth percentile of the general population. In a previous 
study, a similar comparison was made for patients with established AS (27), with an even 
stricter cutoff between normal and impaired mobility (2.5th percentile). This study showed 
that 79% of the patients with AS had impaired spinal mobility compared to the general 
population (27), reflecting that restricted spinal mobility is more prevalent in patients with 
established AS.  
 
In the current study, the most frequently impaired mobility measure in the axSpA group was 
lateral spinal flexion (35%), followed by chest expansion (20%), while the other mobility 
measures had lower proportions of impairment (12-15%). Lateral spinal flexion has also been 
reported to be the most frequently impaired mobility measure in established AS (27), but 
unlike in our early cohort the second most frequently impaired measures were found to be 
lumbar flexion and tragus-to-wall/occiput-to-wall distance (27). This finding may indicate 
that there is a different pattern of mobility impairment in early disease compared to late 
disease. It has been suggested that screening for impairment in mobility in AS can be done 
by assessing lateral spinal flexion and lumbar flexion (27). However, our results do not 
support screening with only these measures, since 28% (21 out of 76) of patients with early 
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axSpA with normal lateral spinal flexion and normal lumbar flexion had impairment in 
another mobility measure.  
 
Because of the natural disease course of progressive restriction in spinal mobility in patients 
with axSpA (28), it could be expected that impaired spinal mobility would occur more often 
among patients with early axSpA than in patients with other causes of chronic back pain. 
However, no differences in proportions of impairment of spinal mobility were found 
between patients with axSpA and patients with chronic back pain of other causes in any of 
the measures. Therefore, our results indicate that mobility measures recommended for 
monitoring axSpA are of limited diagnostic value. Correlations between levels of back pain 
and reduced spinal mobility have previously been demonstrated in patients with chronic 
back pain (29-31), and because patients with axSpA reported less back pain than the other 
subgroups in our study, this may at least partly explain the lack of between-group 
differences. Further, we found differences in the location of back pain, where a larger 
proportion of patients with axSpA have buttock pain and a lower proportion have lumbar 
pain. It is plausible that also the location of back pain could influence the spinal mobility 
measures. Further research is needed to explore which factors are associated with reduced 
spinal mobility in early axSpA.  
 
Even though the proportion of patients with impaired spinal mobility was similar in the 
subgroups, patients with axSpA showed to had better cervical rotation and intermalleolar 
distance than patients with other causes of chronic back pain. The intermalleolar distance is 
a measure of hip abduction and is therefore not included in the spinal mobility measures 
recommended by ASAS (13). However, intermalleolar distance is included in the BASMI (22) 
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and is therefore often reported as an outcome measure in studies with axSpA. Spinal 
mobility is known to be influenced by age (17, 25, 26), height (17, 26), sex (25, 26) and BMI 
(26) in the general population as well as in patients with axSpA (32-35). In our population, 
patients with axSpA were younger, taller, more often men and had lower BMI than patients 
with other causes of chronic back pain, which may have influenced the results. However, the 
categorisation of patients with impairment was adjusted for age (and height) and we did not 
find any differences between the sexes. On the other hand, we were unable to do subgroup 
analyses by BMI, because the extreme groups according to BMI were too small, which is a 
limitation of our study.   
Strengths of our study are the use of wide inclusion criteria (chronic back pain ≥ 3months ≤ 2 
years, onset <45 years), the inclusion of patients from several countries in Europe and having 
followed a thorough examination with assessment recommended by the ASAS. However, 
being a multicentre study, several assessors have collected data, which is a limitation.  
Because the cohort consists of patients with short symptom duration, it is possible that 
some patients not fulfilling the ASAS axSpA criteria at baseline might develop into axSpA 
later. In this and previous publications from this cohort, we therefore grouped patients not 
fulfilling the criteria, but with a higher likelihood of developing axSpA based on baseline 
features as having possible SpA. Included patients may not fully represent the chronic back 
pain population of young age in a community setting and findings are therefore most 
applicable to rheumatologist outpatients’ clinics.  
 
To be specific enough to identify all patients with definitely impaired spinal mobility and 
sensitive enough to capture those with potentially impaired spinal mobility, we chose to 
report the fifth percentile as a cutoff. To our knowledge, a unified definition of impaired 
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mobility has not been established, but this cutoff is in line with articles assessing normative 
values in general population (17, 25, 26). Moreover, data using the 2.5th percentile were very 
similar. 
 
Spinal mobility is impaired in 2 out of 3patients with chronic back pain who are young and 
short symptom duration, but the frequency of impairment is similar in patients with early 
axSpA and those with chronic back pain of other causes.  
Although spinal mobility may play an important role in clinical decision making and 
treatment evaluation in patients with axSpA, our results indicate that mobility measures are 
of no diagnostic value.  
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SUPPLEMENT  
Mobility measurements  
Five measures of spinal mobility and one measure of hip mobility were collected. 
Measurements were performed following the recommendations of the ASAS (1). More 
detailed explanations on the measurement techniques (including images) can be found in 
the slide library of the ASAS website (http://asas-group.org). For each of the measures, the 
better of two tries for each measurement were recorded.  All measurements were recorded 
in cm, except for cervical rotation which was recorded in degrees. All measurements were 
rounded to decimals, except for intermalleolar distance and cervical rotation that were 
rounded to units.  
Supplementary Table 1. Methods used for measuring mobility 
Measure Methods 
Occiput-to-wall 
distances 
The subject stands with heels and back against a wall, with hips and 
knees straight and chin held at usual carrying level. The patient tries to 
touch his/her head against the wall. The distance between occiput and 
the wall is measured with a tape measure. 
Lateral spinal 
flexion 
The subject stands in the same position as for the occiput-to-wall 
distance. Without bending forward, the patient bends sideways as far as 
possible without bending the knees or lifting the heels. The distance 
between the participant’s middle fingertip in the initial position and on 
maximum lateral flexion is measured with a tape measure and averaged 
for both sides. 
Chest 
expansion 
The subject is asked to rest his/her hands on or behind the head. The 
difference between maximal inspiration and expiration is measured 
anteriorly at the fourth intercostal level. 
Lumbar flexion 
 
The subject stands erect with his/her feet about shoulder width apart. 
The assessor marks a point on the patient’s skin on the imaginary line 
between the two posterior superior iliac spines, close to the dimples of 
Venus. A second mark is placed 10cm above the first mark. The patient is 
asked to bend forward as far as possible, keeping the knees straight 
throughout the entire movement, and the distance between the skin 
marks is measured. 
Intermalleolar 
distance 
The subject is lying in a supine position, the knees straight and the feet 
pointing straight up. The patient is asked to separate the legs as far as 
possible and the distance between the medial malleoli is measured. 
Cervical 
rotation 
The subject sits straight on a chair, chin at usual carrying level, and hands 
on the knees. The assessor places the goniometer/myrinometer at the 
top of the subject's head, in line with the nose/north, assuring that the 
assessor can see from the top of the subject's head. The patient then 
rotates the head as much as possible only rotating the neck and the angle 
of the movement is measured and averaged for both sides. 
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Table 1. Characteristics of the patients according to subgroups. Values are n(%) unless 
otherwise specified. 
  All 
patients 
Axial SpA Possible 
SpA 
No SpA  
Characteristics n 393 142 140 111 p 
Male 393 138 (35%)  69 (49%) 39 (28%) 30 (27%) < 0.001α,β 
Age, years  393 31.1 (8.3) 29.7 (8.0) 32.0 (8.3) 31.7 (8.4) 0.04α 
Height, cm 373 175 (9) 177 (10) 172 (9) 175 (9) 0.01α 
Overweight 
(BMI≥25.0) 
372 147 (40%) 43 (33%) 63 (48%) 41 (38%) 0.04α 
Age at onset of 
back pain, years 
391 29.4 (8.2) 28.1 (7.9) 30.4 (8.3) 30.0 (8.4) 0.05 
Duration of back 
pain, months 
392 13.1 (7.2) 13.2 (7.4) 12.4 (6.8) 13.7 (7.4) 0.39 
Back pain intensity, 
NRS 0-10  
352 5.0 (2.3) 4.2 (2.3) 5.3 (2.3) 5.6 (2.2) <0.001α,β 
Location of back pain     
Buttock 389 212 (55%) 88 (63%) 70 (50%) 54 (49%) 0.03α,β 
Lumbar 393 333 (85%) 108 (76%) 124 (89%) 101 (91%) 0.01α,β 
Thoracic 393 137 (35%) 48 (34%) 42 (30%) 47 (42%) 0.12 
SpA features      
IBP 393 246 (63%) 114 (80%) 74 (53%) 58 (52%) <0.001α,β 
Positive family 393 150 (38%) 72 (51%) 55 (39%) 23 (21%) 0.01β,γ 
history 
HLA-B27+ 387 147 (38%) 123 (89%) 20 (15%) 4 (4%) <0.001α,β,γ 
Good response to 
NSAID 
386 136 (35%) 62 (45%) 46 (34%) 28 (25%) 0.01β 
Elevated CRP/ ESR  383 86 (23%) 38 (28%) 48 (35%) 0 <0.001β,γ 
Heel enthesitis 393 64 (16%) 31 (22%) 33 (24%) 0 <0.001β,γ 
Peripheral arthritis 388 54 (14%) 27 (19%) 27 (20%) 0 <0.001β,γ 
Psoriasis 392 38 (10%) 18 (13%) 20 (14%) 0 <0.001β,γ 
IBD 393 33 (8%) 9 (6%) 24 (17%) 0 <0.001α,β,γ 
Uveitis 393 31 (8%) 23 (16%) 8 (6%) 0 <0.001α,β,γ 
Dactylitis 393 21 (5%) 11 (8%) 10 (7%) 0 0.01β,γ 
Sacroiliitis present 
on imaging 
354 62 (17%) 58 (45%) 4 (3%) 0 <0.001 α,β 
     X-ray  19 (5%) 17 (13%) 2 (2%) 0  
     MRI  31 (9%) 30 (23%) 1 (1%) 0  
     X-ray and MRI  12 (3%) 11 (8%) 1 (1%) 0  
Current use of medication     
NSAID 393 273 (70%) 105 (74%) 90 (64%) 78 (70%) 0.21 
DMARD 378 24 (9%) 11 (8%) 13 (10%) 0 0.01 β,γ 
Statistically significant subgroup difference between α axial SpA and possible SpA, β axial SpA 
and no SpA, γ possible SpA and no SpA. AxSpA: axial Spondyloarthritis; BMI: body mass index, 
CRP: C-reactive protein, DMARD: disease modifying anti-inflammatory drug, ESR: erythrocyte 
sedimentation rate, IBD: inflammatory bowel disease, IBP: inflammatory back pain, MRI: 
magnetic resonance imaging, NRS: numeric rating scale, NSAID: non steroid anti-
inflammatory drug, SpA: Spondyloarthritis.  
 
Table 2. Spinal mobility measures according to subgroups. Values are mean (SD) 
expect where indicated.  
 All 
Patients, n 
= 393 
AxSpA, n = 
142 
Possible 
SpA, n = 
140 
No SpA, n 
= 111 
p 
Measure 
Lateral spinal flexion, 
cm, mean (SD), n = 
393 
17.3 (4.4) 17.8 (4.3) 17.2 (4.6) 16.8 (4.2) 0.25 
Chest expansion, cm, 
mean (SD), n = 393 
5.5 (2.0) 5.8 (2.1) 5.3 (2.2) 5.3 (1.6) 0.07 
Cervical rotation, 
degrees, mean (SD),  
n = 389 
72 (12) 74 (11) 70 (13) 71 (10) 0.01 α 
Intermalleolar 
distance, cm, mean 
(SD), n = 390 
114 (20) 118 (19) 110 (21) 112 (18) 0.01 α, β 
Lumbar flexion, 10 
cm Schober’s, cm, 
mean (SD), n = 393 
4.7 (1.2) 4.9 (1.2) 4.7 (1.1) 4.7 (1.1) 0.12 
Occiput-to-wall 
distance, cm, median 
(IQR), n = 393 
0 (0.0-0.0) 0 (0.0-0.0) 0 (0.0-0.0) 0 (0.0-0.0) 0.12 
BASMI (0–10), mean 
(SD), n = 386 
1.9 (0.9) 1.7 (0.8) 2.0 (0.9) 2.0 (0.8) 0.01 α, β 
 
Statistically significant subgroup difference between α axSpA and possible SpA, β 
axSpA, and no SpA. BASMI: Bath Ankylosing Spondylitis Metrology Index, 
axSpA: axial spondyloarthritis, IQR: interquartile range. 
Table 3. Proportion of patients categorised with impaired spinal mobility according to 
subgroups. Values are n (%). 
  All 
Patients 
AxSpA Possible 
SpA 
No SpA  
 
Measure n 393 142 140 111 p 
Lateral spinal flexion 393 158 (40%) 50 (35%) 57 (41%) 51 (46%) 0.22 
Chest expansionγ 373 81 (22%) 27 (20%) 31 (24%) 23 (21%) 0.81 
Cervical rotation 389 69 (18%) 21 (15%) 31 (23%) 17 (15%) 0.18 
Intermalleolar distanceγ 370 63 (17%) 16 (12%) 28 (21%) 19 (18%) 0.13 
Lumbar flexion, 10 cm 
Schober’s 
393 57 (15%) 17 (12%) 20 (14%) 20 (18%) 0.40 
Occiput-to-wall  393 42 (11%) 18 (13%) 18 (13%) 6 (5%) 0.10 
BASMI 386 111 (29%) 29 (21%) 45 (33%) 37 (33%) 0.03 α, β 
Number of impaired mobility measures δ   
 n 367 131 128 108  
1  118 (32%) 38 (29%) 40 (31%) 40 (37%)  
2  68 (19%) 18 (14%) 23 (18%) 27 (25%)  
3  37 (10%) 15 (11%) 15 (12%) 7 (6%)  
≥4  19 (5%) 5 (4%) 9 (7%) 5 (5%)  
Number with at least one impaired mobility measure 
  242 (66%) 76 (58%) 87 (68%) 79 (73%)  
Statistically significant subgroup difference between αaxSpA and possible SpA, β axSpA and 
no SpA. γ Derivation of reference percentile included height, δ patients with complete set of 
mobility measures. AxSpA: axial Spondyloarthritis; BASMI: Bath Ankylosing Spondylitis 
Metrology Index.  
 

